Skip to content
OpenCapital
Get started

Niagen Bioscience, Inc. Common Stock NAGE Q2 2025 earnings

Reported August 6, 2025 · After market close

Revenue$31.1MBeat by $354.8KDiluted EPS$0.04Beat by $0.02
Revenue estimate$30.8M
EPS estimate$0.02

Next report

Aug 5, 2026 (in a month)
Revenue estimate$31.7M
EPS estimate$0.01

Financials

Q2 2025

Income statement

See full
Revenue$31.1M+36.8%
Gross profit$20.2M+47.7%
Operating income$3.2M+1,344%
Net income$3.6M+24,160%
EPS (diluted)$0.04—

Balance sheet

See full
Cash & equivalents$60.5M+117%
Total debt$3.3M+5.4%
Total equity$64.2M+109%
Total assets$91.5M+69.4%

Cash flow

See full
Operating cash flow$1.3M—

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.11B—
Enterprise value$1.06B—
P/E62.8×—
P/S9.6×—

Profitability

See full
Gross margin63.6%+2.8pp
Operating margin14.3%+12.4pp
Net margin15.2%+13.8pp

Returns & leverage

See full
Return on equity37.4%+33.4pp
Debt / equity0.1×-0.1×
Current ratio3.9×+1.1×

Segments

By segment

See full
Consumer Products segment$22.7M+21.7%
Ingredients segment$7.6M+131%
Analytical Reference Standards and Services segment$799.0K+1.0%

Versus estimates

Revenue

Q1 2026$31.5MBeat by $444.0KQ4 2025$33.8MBeat by $2.1MQ3 2025$34.0MBeat by $2.9M
Q2 2025$31.1MBeat by $354.8K
Q1 2025$30.5MBeat by $3.4MQ4 2024$29.1MBeat by $2.4M

Diluted EPS

Q1 2026$0.07Beat by $0.01Q4 2025$0.03Beat by $0.01Q3 2025$0.05Beat by $0.04
Q2 2025$0.04Beat by $0.02
Q1 2025$0.04Beat by $0.02Q4 2024$0.03Beat by $0.01

Ask the moment Niagen Bioscience, Inc. Common Stock reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Niagen Bioscience, Inc. Common Stock report Q2 2025 earnings?
Niagen Bioscience, Inc. Common Stock (NAGE) reported Q2 2025 earnings on August 6, 2025 after market close.
What were Niagen Bioscience, Inc. Common Stock's Q2 2025 revenue and EPS?
Niagen Bioscience, Inc. Common Stock reported revenue of $31.1M and diluted EPS of $0.04 for Q2 2025.
Did Niagen Bioscience, Inc. Common Stock beat estimates in Q2 2025?
Revenue beat the consensus estimate of $30.8M by $354.8K. EPS beat the consensus estimate of $0.02 by $0.02.
How did Niagen Bioscience, Inc. Common Stock's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 36.8% from $22.7M a year earlier.
Where can I find Niagen Bioscience, Inc. Common Stock's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001386570-25-000010) directly on SEC EDGAR. The filing index links above go to sec.gov.